Annovis Bio, Inc. (ANVS)
NYQ · Healthcare · Biotechnology
$1.12
-5.88%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$47.7M
Shares Outstanding
42.6M
Exchange
NYQ
Currency
USD
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.4M) | (9.7M) | (18.0M) | (14.4M) |
| Net Income | (7.3M) | (9.8M) | (17.6M) | (14.8M) |
| Diluted EPS | $-0.37 | N/A | $-0.63 | $-0.40 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (25.5M) | (45.0M) | (26.7M) | (29.7M) |
| Net Income | (25.3M) | (56.2M) | (24.6M) | (28.9M) |
| Diluted EPS | $-3.10 | $-6.23 | $-2.31 | $-1.40 |